Model-informed precision dosing of antimicrobial drugs in pediatrics: experiences from a pilot scale program

Eur J Pediatr. 2023 Sep;182(9):4143-4152. doi: 10.1007/s00431-023-05103-z. Epub 2023 Jul 12.

Abstract

Antibiotics are among the most utilized drugs in pediatrics. Nonetheless, there is a lack in pharmacokinetics information for this population, and dosing criteria may vary between healthcare centers. Physiological variability associated with maturation in pediatrics makes it challenging to reach a consensus on adequate dosing, which is further accentuated in more vulnerable groups, such as critically ill or oncology patients. Model-informed precision dosing is a useful practice that allows dose optimization and attainment of antibiotic-specific pharmacokinetic/pharmacodynamic targets. The aim of this study was to evaluate the needs of model-informed precision dosing of antibiotics in a pediatrics unit, at a pilot scale. Pediatric patients under antibiotic treatment were monitored with either a pharmacokinetic/pharmacodynamic optimized sampling scheme or through opportunistic sampling. Clindamycin, fluconazole, linezolid, meropenem, metronidazole, piperacillin, and vancomycin plasma concentrations were quantified through a liquid chromatography coupled to mass spectrometry method. Pharmacokinetic parameters were estimated using a Bayesian approach to verify pharmacokinetic/pharmacodynamic target attainment. A total of 23 pediatric patients aged 2 to 16 years were included, and 43 dosing regimens were evaluated; 27 (63%) of them required adjustments as follows: 14 patients were underdosed, 4 were overdosed, and 9 patients needed infusion rate adjustments. Infusion rate adjustments were mostly recommended for piperacillin and meropenem; daily doses were augmented for vancomycin and metronidazole, meanwhile linezolid was adjusted for under- and overdosing. Clindamycin and fluconazole regimens were not adjusted at all. Conclusion: Results showcase a lack of antibiotic pharmacokinetic/pharmacodynamic target attainment (particularly for linezolid, vancomycin, meropenem, and piperacillin), and the need for model-informed precision dosing in pediatrics. This study provides pharmacokinetic evidence which can further improve antibiotic dosing practices. What is Known: • Model-informed precision dosing is performed in pediatrics to optimize the treatment of antimicrobial drugs such as vancomycin and aminoglycosides, while its usefulness is debated for other groups (beta-lactams, macrolides, etc.). What is New: • Vulnerable pediatric subpopulations, such as critically ill or oncology patients, can benefit the most from model-informed precision dosing of antibiotics. • Model-informed precision dosing of linezolid, meropenem, piperacillin, and vancomycin is particularly useful in pediatrics, and further research may improve dosing practices altogether.

Keywords: Antibiotics; Liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS); Model-informed precision dosing (MIPD); Pediatrics; Pharmacokinetic/pharmacodynamic (PK/PD) targets.

MeSH terms

  • Anti-Bacterial Agents / therapeutic use
  • Bayes Theorem
  • Child
  • Clindamycin
  • Critical Illness / therapy
  • Fluconazole
  • Humans
  • Linezolid
  • Meropenem
  • Metronidazole
  • Neoplasms* / drug therapy
  • Piperacillin / pharmacokinetics
  • Vancomycin*

Substances

  • Meropenem
  • Vancomycin
  • Linezolid
  • Clindamycin
  • Metronidazole
  • Fluconazole
  • Anti-Bacterial Agents
  • Piperacillin